These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

784 related items for PubMed ID: 15042680

  • 1. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 2. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M.
    Cancer Res; 2002 Nov 01; 62(21):5995-8. PubMed ID: 12414617
    [Abstract] [Full Text] [Related]

  • 3. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 5. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 7. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.
    Stem Cells; 2003 Oct 01; 21(3):315-21. PubMed ID: 12743326
    [Abstract] [Full Text] [Related]

  • 8. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
    Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM.
    Clin Cancer Res; 2003 Apr 01; 9(4):1267-73. PubMed ID: 12684394
    [Abstract] [Full Text] [Related]

  • 9. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
    Tipping AJ, Deininger MW, Goldman JM, Melo JV.
    Exp Hematol; 2003 Nov 01; 31(11):1073-80. PubMed ID: 14585372
    [Abstract] [Full Text] [Related]

  • 10. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T, Miyakawa Y, Iwata S, Kuribara A, Tiganis T, Morimoto C, Ikeda Y, Kizaki M.
    Exp Hematol; 2004 Nov 01; 32(11):1057-63. PubMed ID: 15539083
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 12. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.
    Clin Cancer Res; 2004 Oct 01; 10(19):6661-8. PubMed ID: 15475456
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 14. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
    Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J, Praloran V, Mahon FX.
    Cancer; 2005 Jan 01; 103(1):102-10. PubMed ID: 15558795
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y, Pang J, Pan J.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1806-15. PubMed ID: 20149665
    [Abstract] [Full Text] [Related]

  • 16. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 17. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M, Santucci MA.
    J Pharmacol Exp Ther; 2011 Mar 01; 336(3):596-604. PubMed ID: 21041536
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 20. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 15; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.